Metabolism - Clinical and Experimental
Volume 47, Issue 7 , Pages 824-830, July 1998

Use of a soluble tetrazolium compound to assay metabolic activation of intact β cells

  • Venkatesh Babu G. Segu

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Venkatesh Babu G. Segu, MD, H4/568 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-5148.
    • Section of Endocrinology and the Medical Service, William S. Middleton Memorial Veterans Administration Hospital, Madison, WI, USA
    • Department of Medicine and Section of Endocrinology, University of Wisconsin School of Medicine, Madison, WI, USA
  • ,
  • Guodong Li

      Affiliations

    • Section of Endocrinology and the Medical Service, William S. Middleton Memorial Veterans Administration Hospital, Madison, WI, USA
    • Department of Medicine and Section of Endocrinology, University of Wisconsin School of Medicine, Madison, WI, USA
  • ,
  • Stewart A. Metz

      Affiliations

    • Section of Endocrinology and the Medical Service, William S. Middleton Memorial Veterans Administration Hospital, Madison, WI, USA
    • Department of Medicine and Section of Endocrinology, University of Wisconsin School of Medicine, Madison, WI, USA

Received 2 September 1997; accepted 7 January 1998.

Abstract 

Although assessments of metabolic activation are central to studies of β-cell function, available techniques are tedious, insensitive, and/or require cell disruption. We have investigated the use of a new water-soluble tetrazolium salt, MTS (3-[4,5,dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfophenyl]-2H -tetrazolium, inner salt), in the presence of phenazine methosulfate (PMS), an intermediate electron acceptor that amplifies its signal (fluorescence at 490 nm). During static incubations of glucose-responsive (HIT-T15 or INS-1) dispersed β cells with increasing glucose concentrations, there was a progressive increase in MTS reduction, with a maximum signal-to-noise () ratio of 24 with HIT-T15 cells and 10 with INS-1 cells. This was associated with, but not attributable to, parallel increases in insulin secretion. Pure mitochondrial fuels (α-ketoisocaproate [KIC], methyl pyruvate [MP], or l-glutamine [GLN] + l-leucine [LEU]) also increased the reduction of MTS in INS-1 cells (6.5-, 4.8-, and 14.4-fold, respectively), but generally less than glucose, suggesting a major role of glycolysis in the signal induced by glucose. Inhibitors of glucose metabolism (mannoheptulose [MH], Iodoacetate [IA], or 2-deoxyglucose [2-DG]) markedly reduced the glucose-stimulated MTS signal. In comparison to another tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), MTS assay provided a better ratio with glucose or other nutrient secretagogues. Extant theory holds that activation of mitochondrial dehydrogenases by increments in Ca2+ influx couples glycolysis to mitochondrial oxidation of glucose-derived fuels. However, reduction of fuel-induced calcium influx (by Ca2+-free medium or diazoxide [DZX]) or direct stimulation of calcium influx (by 40 mmol/L K+) failed to significantly modulate the signal, arguing against this theory. We conclude that the MTS assay is a facile test that reflects the global metabolic function of insulin-secreting β cells. Furthermore, since this assay does not require disruption of cells to solubilize the formazan product, and therefore also allows concomitant measurement of insulin secretion, it offers considerable advantages over earlier methods.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the Veterans Administration and the National Institutes of Health (DK 37312).

PII: S0026-0495(98)90120-2

Metabolism - Clinical and Experimental
Volume 47, Issue 7 , Pages 824-830, July 1998